Printer Friendly

CYGNUS 'WAKING HOURS' NICOTINE PATCH SHOWS IMPRESSIVE RESULTS IN A RECENT STUDY

 REDWOOD CITY, Calif., Sept. 10 /PRNewswire/ -- A one year study of the efficacy of the nicotine patch designed, developed and manufactured by Cygnus Therapeutic Systems (NASDAQ: CYGN), in conjunction with typical physician counseling, yielded a significant quit-rate of 25 percent. The sustained non-smoking rates for patients using the Cygnus patch were almost three times higher than those wearing a placebo (25 percent vs. 9 percent).
 The study was conducted by pulmonologist David P.L. Sachs, M.D., director of the Palo Alto Center for Pulmonary Disease Prevention, cardiologist Urban Sawe, M.D., Ph.D., and behavioral pharmacologist Scott J. Leishow, Ph.D. Importantly, the study was designed as a model for the smoking cessation therapy a physician could provide for patients in the normal course of office visits, but without intensive behavior modification programs like group therapy.
 One year after the start of this study, it was found that 25 percent of those who used the Cygnus "waking hours" patch (marketed by Parke- Davis as Nicotrol(R)) were still not smoking, compared to only 9 percent who were treated with placebo patches. The difference is statistically significant (p less than 0.001).
 "The results of this study are encouraging," stated Gregory B. Lawless, Ph.D., president and chief executive officer of Cygnus Therapeutic Systems. "We know there is strong consumer interest in products which can successfully help them to stop smoking. This trial indicates that when used as a part of a typical physician counseling program, our 'waking hours' nicotine patch may help achieve long term smoking cessation without the need for special behavior modification efforts. These findings may have important implications for nicotine patches eventually being approved for over-the-counter sales."
 The study also indicated a low incidence of side effects. For example, there was no difference in skin irritation between the active patch and the placebo patch wearers. Also, no abnormal dreams were recorded using the "waking hours" patch. Cygnus' nicotine patch is the only one on the market designed exclusively for use only during the waking hours.
 Cygnus Therapeutic Systems is a leader in the development of advanced transdermal drug delivery systems. The company's focus is on developing products for the smoking cessation, hormone replacement, non- invasive glucose monitoring and consumer products markets. The company has more than a dozen products in various stages of development, including a proprietary 7-day estradiol transdermal system for the treatment of menopausal symptoms which is in phase III clinical trials.
 The study was conducted independently by Dr. Sachs and his colleagues. For detailed information about the methodology and findings, contact David P.L. Sachs, M.D. at 415-327-9494.
 -0- 9/10/93
 /CONTACT: Craig Carlson of Cygnus, 415-369-4300/
 (CYGN)


CO: Cygnus Therapeutic Systems ST: California IN: MTC SU:

LH-MC -- SJ002 -- 0919 09/10/93 17:17 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 10, 1993
Words:465
Previous Article:PUBLIC ASSISTANCE ROLLS INCREASE AGAIN IN JULY
Next Article:PRATT & WHITNEY ROCKET ENGINE SUCCESSFULLY POWER FIRST PUBLIC FLIGHT OF DELTA CLIPPER
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters